


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A compound of formula I



linked to a molecule comprising B-10, wherein X is CN, OH, CH_3 , adenosyl or a molecule comprising B-10 and optionally linked to a linker comprising a detectable radionuclide or a therapeutic radionuclide; or a pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is directly linked to the 6-position of the compound of formula I or is directly linked to the b, d or e-carboxamide group of the compound of formula I.

Claim 3 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is linked by a linker to the 6-position of the compound of formula I or is linked by a linker to the b, d or e-carboxamide group of the compound of formula I.

Claim 4 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is linked to the b-carboxamide group of the compound of formula I.

Claim 5 (currently amended): The compound of claim 1, wherein the ~~molecule~~ molecule comprising B-10 is linked to the d-carboxamide group of the compound of formula I.

Claim 6 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is linked to the e-carboxamide group of the compound of formula I.

Claim 7 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is linked to the b-carboxamide group and a second molecule comprising B-10 is linked to the d-carboxamide group of the compound of formula I.

Claim 8 (previously presented): The compound of claim 1, wherein molecule comprising B-10 is linked to the 6-position of the compound of formula I.

Claim 9 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 contains 1 to about 20 boron atoms, inclusive.

Claim 10 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is an amino acid, a carbohydrate, a nucleoside or a carborane.

Claim 11 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is o-carborane, m-carborane or p-carborane.

Claim 12 (previously presented): The compound of claim 1, wherein the molecule comprising B-10 is o-carborane.

Claim 13 (previously presented): The compound of claim 3, wherein at least one linker is of the formula W-A-Q wherein A is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, or (C₆-C₁₀)aryl, wherein W and Q are each independently -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)₂-, -N(R)-, -C(=O)-, or a direct bond; wherein each R is independently H or (C₁-C₆)alkyl.

Claim 14 (previously presented): The compound of claim 13, wherein W is NH₂ or COOH and Q is NH₂ or COOH.

Claim 15 (previously presented): The compound of claim 13, wherein A is (C₁-C₆)alkyl.

Claim 16 (previously presented): The compound of claim 3, wherein at least one linker is about 5 angstroms to about 50 angstroms, inclusive.

Claim 17 (previously presented): The compound of claim 3, wherein at least one linker comprises a therapeutic radionuclide or a diagnostic radionuclide.

Claim 18 (previously presented): The compound of claim 17, wherein the therapeutic radionuclide is a metallic radionuclide.

Claim 19 (previously presented): The compound of claim 17, wherein the diagnostic radionuclide is a metallic radionuclide.

Claim 20 (previously presented): The compound of claim 17, wherein the diagnostic radionuclide is a non-metallic radionuclide.

Claim 21 (previously presented): The compound of claim 3, wherein at least one linker is a divalent radical formed from a peptide.

Claim 22 (previously presented): The compound of claim 3, wherein at least one linker is a divalent radical formed from an amino acid.

Claim 23 (previously presented): The compound of claim 3, wherein at least one linker is poly-L-glutamic acid, poly-L-aspartic acid, poly-L-histidine, poly-L-ornithine, poly-L-serine, poly-L-threonine, poly-L-tyrosine, poly-L-leucine, poly-L-lysine-L-phenylalanine, poly-L-lysine or poly-L-lysine-L-tyrosine.

Claim 24 (previously presented): The compound of claim 1, wherein the compound of formula I is also linked to a linker comprising a detectable radionuclide or a therapeutic radionuclide.

Claim 25 (previously presented): A compound of formula I




linked to one or more groups of the formula Q-L-W-Det, wherein X is CN, OH, CH₃, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein Det is a chelating group comprising Gd-157; L is a linker or absent; and W and Q are each independently – N(R)C(=O)–, –C(=O)N(R)–, –OC(=O)–, –C(=O)O–, –O–, –S–, –S(O)–, –S(O)₂–, –N(R)–, –C(=O)–, or a direct bond; wherein each R is independently H or (C₁–C₆)alkyl; or a pharmaceutically acceptable salt thereof.

Claim 26 (previously presented): The compound of claim 25, wherein the group of the formula Q-L-W-Det is linked to the b-carboxamide group, d-carboxamide group, e-carboxamide group or the 6-position of the compound of formula I.

Claim 27 (previously presented): The compound of claim 25, wherein the group of the formula Q-L-W-Det is linked to the b-carboxamide group and a second group of the formula Q-L-W-Det is linked to the d-carboxamide group of the compound of formula I.

Claim 28 (previously presented): The compound of claim 25, wherein the group of the formula Q-L-W-Det is between about 20 and about 500 angstroms, inclusive, in length.


Claim 29 (currently amended): The compound of claim 25, wherein at least one chelating group is ethylenediaminetetraacetic acid (EDTA); diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane-N,N',N'',N'''-tetraacetic acid (15N4); 1,4,7-triazacyclononane-N,N',N''-triacetic acid (9N3); 1,5,9-triazacyclododecane-N,N',N''-triacetic acid (12N3); N-[N-[N-[(benzoylthio) acetyl]glycyl]glycyl]glycine (MAG3); or a cyclohexane-based metal chelator (DCTA) of the formula



wherein R^3 ~~may be~~ is $(C_1-C_4)alkyl-$ or CH_2CO_2- , and M is a metal or nonmetal cation.

Claim 30 (previously presented): The compound of claim 25, wherein at least one chelating group is diethylenetriaminepentaacetic acid (DTPA) comprising Gd-157.

Claim 31 (previously presented): A compound of formula I



linked to a molecule comprising B-10; wherein the compound of formula I is linked to a group of the formula Q-L-W-Det, wherein X is CN, OH, CH₃, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein


- a) Det is a chelating group comprising a therapeutic radionuclide or a diagnostic radionuclide;

- b) L is a linker or absent; and
c) Q and W are each independently $-N(R)C(=O)-$, $-C(=O)N(R)-$, $-OC(=O)-$, $-C(=O)O-$, $-O-$, $-S-$, $-S(O)-$, $-S(O)_2-$, $-C(=O)-$, $-N(R)-$, or a direct bond; wherein each R is independently H or (C_1-C_6) alkyl;
or a pharmaceutically acceptable salt thereof.

Claim 32 (previously presented): The compound of claim 31, wherein at least one of the radionuclides is Tc^{99m} , In^{111} , In^{110} , Gd^{157} or Y^{86} .

Claim 33 (previously presented): The compound of claim 31, wherein a molecule comprising B-10 is linked to a b-carboxamide group, d-carboxamide group, e-carboxamide group or the 6-position of the compound of formula I.

Claim 34 (currently amended): The compound of claim 31, wherein at least one chelating group is ethylenediaminetetraacetic acid (EDTA); diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane- N,N',N'',N''' -tetraacetic acid (DOTA); 1,4,8,11-tetraazacyclotetradecane- N,N',N'',N''' -tetraacetic acid (TETA); 1,4,8,12-tetraazacyclopentadecane- N,N',N'',N''' -tetraacetic acid (15N4); 1,4,7-triazacyclononane- N,N',N'' -triacetic acid (9N3); 1,5,9-triazacyclododecane- N,N',N'' -triacetic acid (12N3); N-[N-[N-[(benzoylthio) acetyl]glycyl]glycyl]glycine (MAG3); or a cyclohexane-based metal chelator (DCTA) of the formula



wherein R^3 ~~may be~~ is (C_1-C_4) alkyl- or CH_2CO_2- , and M is a metal or nonmetal cation.

Claim 35 (previously presented): The compound of claim 31, wherein at least one chelating group is diethylenetriaminepentaacetic acid (DTPA) comprising Gd-157.

Claim 36 (currently amended): The compound of claim 31, wherein the molecule comprising B-10 contains ~~about~~ 1 to about 20 boron atoms, inclusive.

Claim 37 (previously presented): The compound of claim 31, wherein the molecule comprising B-10 is an amino acid, a carbohydrate, a nucleoside or a carborane.

Claim 38 (previously presented): The compound of claim 31, wherein the molecule comprising B-10 is o-nido-carborane, m-nido-carborane or p-nido-carborane.

Claim 39 (previously presented): The compound of claim 31, wherein the molecule comprising B-10 is o-carborane.


Claim 40 (previously presented): The compound of claim 31, wherein the molecule comprising B-10 is directly linked to the 6-position or to the b, d or e-carboxamide group of the compound of formula I.

Claim 41 (previously presented): The compound of claim 31, wherein the compound of formula I is linked to the molecule comprising B-10 through a linker.

Claim 42 (previously presented): The compound of claim 41, wherein the linker comprises a non-metallic radionuclide.

Claim 43 (previously presented): The compound of claim 41, wherein the linker is about 5 angstroms to about 50 angstroms, inclusive.

Claim 44 (currently amended): The A compound of claim 1, further comprising a formula I



linked to a molecule comprising B-10, wherein X is CN, OH, CH₃, adenosyl or a molecule comprising B-10 comprising at least one detectable radionuclide or a therapeutic radionuclide; or a pharmaceutically acceptable salt thereof.

Claim 45 (previously presented): The compound of claim 44, wherein the detectable radionuclide is a non-metallic radionuclide.

Claim 46 (previously presented): The compound of claim 45, wherein the non-metallic radionuclide is Carbon-11, Fluorine-18, Bromine-76, Iodine-123 or Iodine-124.

Claim 47 (previously presented): The compound of claim 44, wherein the detectable radionuclide is directly linked to the compound of formula I.

Claim 48 (previously presented): The compound of claim 44, wherein the detectable radionuclide is linked by a linker to the compound of formula I.

Claim 49 (previously presented): The compound of claim 48, wherein the linker is of the formula W-A wherein A is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, or (C₆-C₁₀)aryl, wherein W is -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)₂-, -N(R)-, -C(=O)-, or a direct bond; wherein each R is independently H or (C₁-C₆)alkyl, and wherein A is substituted with one or more non-metallic radionuclides.

Claim 50 (previously presented): The compound of claim 48, wherein the linker is about 5 angstroms to about 50 angstroms, inclusive.


Claim 51 (previously presented): The compound of claim 48, wherein the linker is a divalent peptide or amino acid.

Claim 52 (previously presented): The compound of claim 48, wherein the linker is poly-L-glutamic acid, poly-L-aspartic acid, poly-L-histidine, poly-L-ornithine, poly-L-serine, poly-L-threonine, poly-L-tyrosine, poly-L-leucine, poly-L-lysine-L-phenylalanine, poly-L-lysine or poly-L-lysine-L-tyrosine.

Claim 53 (previously presented): The compound of claim 48, wherein the linker is linked to the 6-position of the compound of formula I or is linked to the a b-, d- or e-carboxamide group of the compound of formula I.

Claims 54-64 (canceled)

Claims 65 (previously presented): A compound of formula I



linked

- 1) to a molecule comprising B-10 or a chelating group comprising Gd-157; and
- 2) to at least one molecule of the formula Q-L-W-Det, wherein X is CN, OH, CH₃, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein each Det is independently a chelating group comprising a metallic radionuclide; each L is independently a linker or absent; and each W and Q are each independently -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)₂-,

-C(=O)-, -N(R)-, or a direct bond; wherein each R is independently H or (C₁-C₆)alkyl;
or a pharmaceutically acceptable salt thereof.

Claim 66 (previously presented): The compound of claim 1 or 44, wherein the compound of formula I is also linked to a group comprising Gd-157.

Claim 67 (previously presented): The compound of claim 66, wherein the group comprising Gd-157 has the formula Q-L-W-Det, wherein X is CN, OH, CH₃, adenosyl, a molecule comprising B-10 or Q-L-W-Det; wherein Det is a chelating group comprising Gd-157; L is a linker or absent; and W and Q are each independently -N(R)C(=O)-, -C(=O)N(R)-, -OC(=O)-, -C(=O)O-, -O-, -S-, -S(O)-, -S(O)₂-, -N(R)-, -C(=O)-, or a direct bond; wherein each R is independently H or (C₁-C₆)alkyl.

Claim 68 (previously presented): A composition comprising a compound of any one of claim 1-53 or 65-67 and a pharmaceutically acceptable carrier.

Claim 69-74 (canceled):